Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Assets Average (2017 - 2025)

Historic Assets Average for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $73.0 million.

  • Vistagen Therapeutics' Assets Average fell 2506.02% to $73.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $73.0 million, marking a year-over-year decrease of 2506.02%. This contributed to the annual value of $104.0 million for FY2025, which is 4369.98% up from last year.
  • As of Q4 2025, Vistagen Therapeutics' Assets Average stood at $73.0 million, which was down 2506.02% from $74.9 million recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Assets Average peaked at $127.4 million during Q1 2024, and registered a low of $18.1 million during Q2 2023.
  • For the 5-year period, Vistagen Therapeutics' Assets Average averaged around $78.5 million, with its median value being $84.6 million (2022).
  • In the last 5 years, Vistagen Therapeutics' Assets Average surged by 185938.43% in 2021 and then tumbled by 7291.63% in 2023.
  • Over the past 5 years, Vistagen Therapeutics' Assets Average (Quarter) stood at $95.5 million in 2021, then crashed by 63.14% to $35.2 million in 2022, then surged by 146.08% to $86.6 million in 2023, then grew by 12.43% to $97.4 million in 2024, then dropped by 25.06% to $73.0 million in 2025.
  • Its Assets Average stands at $73.0 million for Q4 2025, versus $74.9 million for Q3 2025 and $76.6 million for Q2 2025.